DSIP

It crosses the blood-brain barrier and has been described as a multifunctional regulatory peptide with stress-protective, adaptive, and possibly geroprotective activity in animals. The human evidence is genuinely thin, dated, and equivocal.

A small cluster of studies from the early-to-mid 1980s (largely from Schneider-Helmert and colleagues) reported that subcutaneous or intravenous DSIP injections improved sleep in patients with severe insomnia — sometimes with normalization of sleep structure after repeated administration — and a separate open pilot study reported lowered pain levels and reduced depressive states in patients with chronic pain syndromes (migraine, vasomotor headache, tinnitus, psychogenic pain).

Some of the 1980s sleep work was in fact double-blind and placebo-controlled rather than open-label: Schneider-Helmert's own 7-night placebo-controlled trial (n=14) reported substantial sleep improvement, but an independent double-blind crossover trial by Monti and colleagues found that any sleep improvement under DSIP was 'of little clinical significance' and that DSIP did not modify slow-wave sleep.

So even the controlled human data are small, single-investigator-dominated for the positive findings, and contradicted by the one independent controlled trial. All of this is now around four decades old.

Importantly, the evidence is not uniformly positive: a 2009 randomized study using DSIP as an adjunct to isoflurane anaesthesia found that DSIP paradoxically REDUCED delta rhythm, increased the bispectral index (i.e. lightened anaesthetic depth), raised heart rate, and reduced heart-rate variability — the opposite of a simple sleep-deepening effect — and a CSF study in schizophrenic volunteers only correlated endogenous DSIP-like immunoreactivity with slow-wave sleep, without testing exogenous DSIP.

Most of the mechanistic and longevity work since the 1990s has been in rats and mice: Russian groups report antioxidant/geroprotective effects, stress protection, and (with the 'Deltaran' DSIP preparation) modestly extended lifespan and reduced spontaneous carcinogenesis in mice.

Here is the honest, load-bearing caveat: there is no modern, adequately-powered, independently-replicated, placebo-controlled human efficacy trial of DSIP for sleep, pain, or anything else.

The supportive human data are small, decades old, and dominated by a single investigator; the one independent controlled sleep trial found the effect clinically negligible, and the one controlled anaesthesia study found an effect opposite to the popular 'sleep peptide' framing.

DSIP is not approved by any regulator, it is not a lawful dietary-supplement ingredient, and the material sold online is an unregulated grey-market injectable research chemical with no guarantee of identity, purity, or sterility, and no characterised long-term human safety.

The evidence here is therefore UNSCORED: a historically interesting neuropeptide with weak, dated, and partly contradictory human data, sandboxed out of all goal- and stack-based recommendations.